Search
for
Sort by
Research 451–480 of 506
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- The pathophysiology of delayed ejaculation
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
- Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
- Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
- What Ages Hair?
- Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA
- Psychology’s medicalization of male baldness
- Non-surgical management of BPH: An updated review of current literature and state of the art on natural compounds and medical therapy
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
- Clinical use of 5α-reductase inhibitors
- The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Inhibitory Effects of Pueraria mirifica Aqueous Extracts on 5α-reductase and Prostate Histomorphometry in Testosterone-induced Benign Prostatic Hyperplasia Sprague Dawley Rats
- A Review on Drug Induced Alopecia
- Hair Loss in Men and Women
- Steroid Hormones of Reproduction and Sexual Development
- Male pattern baldness
- The childbearing years: hair diseases
- 3a-Phenylhexahydropentalene-1,6-dione
- A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole
- 8주 지구성 훈련이 랫 전립선의 자가포식과 전립선비대증에 미치는 영향
- 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
- Medical treatments for male and female pattern hair loss
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- Prostate Cancer Early Detection, Version 2.2015